The Lannebo Sverige fund rose 7.4 percent in February, outperforming its benchmark index which gained 4.5 percent. Since the turn of the year, the fund has returned 6.9 percent, in line with the index which has also increased by 6.9 percent. This is according to a monthly report authored by Martin Wallin and Robin Nestor.

The managers initially note that U.S. manufacturing PMI data took a clear step upward during the month, suggesting an improving economic outlook. Long-term market interest rates fell simultaneously, with the U.S. ten-year yield once again trading around 4 percent.

The primary contributors to the fund's performance were Nokia, Sobi, and companies within the forestry and engineering sectors. The managers particularly highlight that the positive price trend in major engineering firms continued, with several companies reaching new record highs.

Bioarctic reported a strong fourth quarter driven by the success of the Alzheimer's drug Leqembi. Net sales rose to SEK 184 million, and operating profit turned positive. With a cash balance of nearly SEK 2.2 billion and new global approvals for the drug, the board proposed a dividend of SEK 2 per share.

"Leqembi continued to expand with new approvals in countries including Brazil, Canada, and the UK, as well as the launch of the new subcutaneous weekly treatment in the US," the managers write.

During the month, the managers chose to increase holdings in the three major banks SEB, Nordea, and Swedbank. Meanwhile, divestments were made in Essity, Nokia, and SKF.

The largest equity holdings in the fund's portfolio at the end of the month were Ericsson, SKF, and Autoliv, with portfolio weights of 8.8, 7.0, and 6.6 percent, respectively.

Lannebo Sverige, %February, 2026
Fund M/M, change in percent7.4
Index M/M, change in percent4.5
Fund YTD, change in percent6.9
Index YTD, change in percent6.9